Protagenic Therapeutics Warrant
PTIXW
PTIXW was delisted on the 2nd of January, 2026.
1 hedge funds and large institutions have $69K invested in Protagenic Therapeutics Warrant in 2021 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
1.18% less ownership
Funds ownership: 2.25% → 1.07% (-1.2%)
50% less funds holding
Funds holding: 2 → 1 (-1)
52% less capital invested
Capital invested by funds: $143K → $69K (-$74K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$73.7K |
PTIXW Hedge Fund Activity: Q4 2021 in Review
1 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Protagenic Therapeutics Warrant (PTIXW) for Q4 2021, worth a combined $69K — down 52% from $143K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PTIXW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was Warberg Asset Management, cutting an estimated $73.7K.
- 1 institutional investor held Protagenic Therapeutics Warrant (PTIXW) as of Q4 2021, down from 2 in Q3 2021.
- Funds reported $69K of Protagenic Therapeutics Warrant stock for Q4 2021, down 52% quarter-over-quarter.
- 0 funds opened new Protagenic Therapeutics Warrant positions in Q4 2021 and 1 closed out, a net change of -1 holder.
- The largest Protagenic Therapeutics Warrant seller in Q4 2021 was Warberg Asset Management, an estimated $73.7K sold.
Based on aggregated 13F filings for Q4 2021.